Abstract 3050
Background
Although surgical resection is the main treatment for rectal cancer, the optimal surgical protocol for elderly patients with rectal cancer remains controversial. Robot-assisted surgery has the following advantages: smaller wounds, less blood loss, quicker recovery, early recovery, and high rate of anal preservation. This study evaluated the feasibility of robot-assisted surgery in elderly patients with rectal cancer.
Methods
This retrospective study enrolled 125 patients aged 28–93 years diagnosed with stage I–III rectal cancer who underwent robot-assisted surgery between May 2013 and April 2018 in a single institution.
Results
In total, 125 patients with rectal cancer, including 100 nonelderly (aged <70 years) and 25 elderly (aged ≥70 years) patients, who underwent robot-assisted surgery were recruited. Between the patient groups, the incidence of overall postoperative complications and postoperative length of hospital stay did not differ significantly (p = 0.930 and 0.095, respectively). No surgical related deaths were noted. The disease-free and overall survival did not differ significantly between the 2 groups (p = 0.610 and 0.298, respectively).
Conclusions
Robot-assisted surgery for rectal cancer is an appropriate approach that is well tolerated in elderly patients, with similar results as for the non-elderly patients. Oncological outcomes, including postoperative complications and survival, did not depend on patient age. Thus, in elderly patients, robot-assisted surgery is a safe and feasible surgical modality for treating operable rectal cancer and leads to age-independent postoperative outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-Chih Su.
Funding
Kaohsiung Medical University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract